Search results

2371 results

Sorted by Relevance . Sort by Date

  1. Acceptability of drug misuse prevention interventions:- How acceptable are drug misuse prevention interventions among groups vulnerable to drug misuse in the UK? How acceptable are drug misuse prevention interventions among practitioners in the UK? How can acceptability be improved for groups that are vulnerable to drug misuse and practitioners?

    Recommendation ID NG64/4 Question Acceptability of drug misuse prevention interventions:- How acceptable are drug misuse prevention interventions

  2. Further research into endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence should clearly define the patient groups being treated. It should also report the clinical impact in terms of quality of life and long-term outcomes. NICE may review the procedure on publication of further evidence.

    Recommendation ID IPG393/1 Question Further research into endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence

  3. Further research into implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis should include comparative studies against existing forms of management. Studies should record patient selection, functional outcomes, quality of life and complications. They should also report the nature and timing of any further surgery on the knee and the effect of removing the device. A minimum follow-up period of 2–3 years is needed. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG512/1 Question Further research into implantation of a shock or load absorber for mild to moderate symptomatic medial

  4. Further research into joint distraction for ankle osteoarthritis should include comparative studies against the natural history of the disease and against other forms of management. Studies should record patient selection, pain relief, functional outcomes, complications, and quality of life in the long term. They should also report the nature and timing of any further surgery on the ankle.Minimising loss to follow-up is of particular importance. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG538/1 Question Further research into joint distraction for ankle osteoarthritis should include comparative studies

  5. Further research into joint distraction for knee osteoarthritis without alignment  correction should include comparative studies against existing forms of management. Studies should record patient selection, joint space measurements in the medium to long term, functional outcomes, quality of life and complications. They should also report the nature and timing of any further surgery on the knee. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG529/1 Question Further research into joint distraction for knee osteoarthritis without alignment correction should

  6. Further research into open reduction of slipped capital femoral epiphysis should clearly describe details of clinical presentation (for example, Loder classification), the degree of slip, its stability, and the surgical technique used; including whether surgical dislocation of the hip was done. Outcomes from 2 years onwards should include degree of correction, occurrence of avascular necrosis and need for subsequent hip surgery (and its timing).

    Recommendation ID IPG511/1 Question Further research into open reduction of slipped capital femoral epiphysis should clearly describe details

  7. Further research into percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices should take the form of well-conducted trials, which should define patient selection, treatment protocols and location and types of arterial lesions treated, and report long-term patency outcomes. NICE may review this procedure on publication of further evidence.

    Recommendation ID IPG380/1 Question Further research into percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision

  8. Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA) kits (LISA-TRACKER, IDKmonitor and Promonitor) is recommended, specifically on:- the best methods to measure tumour necrosis factor (TNF)-alpha-inhibitor levels in the presence of antibodies to TNF-alpha inhibitors- developing primary reference standards- the accuracy for predicting clinical state- clinically meaningful thresholds.

    Recommendation ID DG22/1 Question Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA)

  9. In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed that further research into the treatment benefit of burosumab in young people aged 13 years and over would relieve some of the clinical uncertainty in an age group covered by the marketing authorisation.

    Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed